At a glance
ClinicalIndex Comparison RecordN/ACompleted· 592 target
Drug / intervention
Didanosine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Implementing Anti-Retroviral Therapy in Resource-Constrained Settings: A Randomized Controlled Trial to Assess the Effect of Integrated Tuberculosis and HIV Care on the Incidence of AIDS-Defining Conditions or Mortality in Subjects Co-Infected With Tuberculosis and HIV
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Sep 21, 2004·Updated Mar 29, 2010
In Brief
A clinical study evaluating Didanosine, Efavirenz, and 2 other interventions for HIV Infections and Tuberculosis. Completed, enrolled 592 participants across 2 sites.
Detailed Summary
Tuberculosis (TB), a bacterial infection common in HIV infected people, is a major problem in developing countries. The purpose of this study is to test the effectiveness of a combined treatment strategy using directly observed therapy (DOT) for HIV infected patients with TB. Participants will be recruited from resource-poor communities in Durban, South Africa.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Tuberculosis
CountriesSouth Africa
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2004
Enrollment StartAug 2009
TodayJul 2026
First PostedSep 21, 2004
Enrollment StartAug 1, 2009
TodayJul 2, 2026
Posted 21.8 years ago
Interventions
Didanosinedrug
Efavirenzdrug
Lamivudinedrug
Standard TB treatmentdrug